Skip to content

Type 2 diabetes — overview

TL;DR — Type 2 diabetes (T2D) is a progressive disorder of insulin resistance and β-cell failure affecting an estimated 536.6 million adults (10.5% of the world's 20–79-year-olds) in 2021, projected to reach 783.2 million by 2045, with health expenditures of $966 billion/year (Sun 2022, PMID 34879977). Two therapeutic revolutions define the current era: SGLT2 inhibitors and GLP-1 receptor agonists reduce cardiovascular death, kidney failure, and (for GLP-1RAs) stroke independent of glucose lowering (Zinman 2015, PMID 26378978; Marso 2016, PMID 27295427; Palmer 2021, PMID 33441402), and dual-agonist incretin therapy produces ~21% body-weight loss, blurring the boundary between diabetes and obesity medicine (Jastreboff 2022, PMID 35658024). Meanwhile the DiRECT trial showed T2D is not inevitably permanent: 46% of primary-care patients achieved remission at one year with an intensive weight-management program (Lean 2018, PMID 29221645). Current ADA/EASD positions embed weight, cardiovascular, and kidney outcomes as co-primary goals beside glucose (Davies 2022, PMID 36148880). The central open question is durability — of remission, of incretin-era benefits, and of health systems' ability to pay for them.

Definition and diagnostic anchors

  • T2D is diagnosed by standard glycemic thresholds (fasting glucose ≥126 mg/dL, 2-h OGTT ≥200 mg/dL, HbA1c ≥6.5%, or random glucose ≥200 mg/dL with symptoms), maintained in the ADA Standards of Care (ADA 2026, PMID 41358893).
  • Remission is now formally defined: HbA1c <6.5% at least 3 months after stopping glucose-lowering medication (Riddle 2021, PMID 34462270).
  • Mechanistically, the "twin cycle" model frames T2D as excess liver and pancreas fat in susceptible individuals, reversible by substantial calorie restriction (Taylor 2016, PMID 30058916).

Epidemiology and burden

Figure Value Source
Adults (20–79) with diabetes, 2021 536.6 million (10.5%) (Sun 2022, PMID 34879977)
Projection 2045 783.2 million (12.2%) (Sun 2022, PMID 34879977)
Global diabetes health expenditure, 2021 $966 billion; projected $1,054 billion by 2045 (Sun 2022, PMID 34879977)
GBD 2050 projection (all diabetes) >1.3 billion people (GBD 2021 Diabetes Collaborators 2023, PMID 37356446)
Urban vs rural prevalence, 2021 12.1% vs 8.3% (Sun 2022, PMID 34879977)
  • The largest relative growth to 2045 is expected in middle-income countries (+21.1%) (Sun 2022, PMID 34879977).
  • Youth-onset T2D is aggressive: in the TODAY cohort, complications accumulated rapidly through young adulthood (TODAY Study Group 2021, PMID 34320286).
  • Complications burden remains dominated by cardiovascular and kidney disease; excess mortality and cardiovascular risk track with age at diagnosis and risk-factor control (Rawshani 2017, PMID 28402770).

Mechanism sketch

  • Chronic energy surplus → ectopic fat in liver and pancreas → hepatic insulin resistance plus β-cell dedifferentiation in susceptible individuals; the reversibility of β-cell failure with ~15 kg weight loss is the strongest evidence for this model (Taylor 2016, PMID 30058916; Lean 2018, PMID 29221645).
  • Remission probability is dose-dependent on weight loss: 86% of DiRECT participants losing ≥15 kg achieved remission vs 7% with 0–5 kg loss (Lean 2018, PMID 29221645).
  • Glycemia is only one axis: SGLT2i and GLP-1RA outcome benefits are largely independent of HbA1c lowering, implying hemodynamic, natriuretic, anti-inflammatory, and weight-mediated pathways (Palmer 2021, PMID 33441402).

Treatment landscape

Glycemic legacy evidence - UKPDS 33/34 established intensive glucose control (sulfonylurea/insulin; metformin in overweight) reduces microvascular complications (UKPDS 1998, PMID 9742976; PMID 9742977). The 10-year post-trial follow-up revealed the "legacy effect": emergent reductions in MI (15%) and all-cause death (13%) (Holman 2008, PMID 18784090), and 24-year extended follow-up (UKPDS 91) shows the glycemic and metformin legacy effects have not waned — 10% lower all-cause death, 17% lower MI with early intensive control (Adler 2024, PMID 38772405). - GRADE compared four second-line agents head-to-head: the glycaemic-outcomes report established relative durability, while a companion report assessed microvascular and cardiovascular outcomes (GRADE 2022, PMID 36129996; PMID 36129997).

The GLP-1/SGLT2 era (anchor trials)

Trial Agent Headline result Source
EMPA-REG OUTCOME (2015) empagliflozin MACE HR 0.86; CV death −38%, HF hospitalization −35%, all-cause death −32% (Zinman 2015, PMID 26378978)
LEADER (2016) liraglutide MACE HR 0.87; CV death HR 0.78 (Marso 2016, PMID 27295427)
SUSTAIN-6 (2016) semaglutide CV outcomes in T2D (Marso 2016, PMID 27633186)
PIONEER 6 (2019) oral semaglutide CV safety of first oral GLP-1RA (Husain 2019, PMID 31185157)
CREDENCE (2019) canagliflozin renal composite HR 0.70; ESKD −32% (Perkovic 2019, PMID 30990260)
SURPASS-2 (2021) tirzepatide HbA1c −2.30 pp (15 mg), superior to semaglutide 1 mg (Frías 2021, PMID 34170647)
SURMOUNT-1 (2022) tirzepatide (obesity) −20.9% body weight at 72 weeks (15 mg) (Jastreboff 2022, PMID 35658024)
SELECT (2023) semaglutide 2.4 mg (obesity, no diabetes) MACE HR 0.80 (Lincoff 2023, PMID 37952131)
FLOW (2024) semaglutide (T2D + CKD) kidney-disease progression reduced (Perkovic 2024, PMID 38785209)
SURMOUNT-2 (2023) tirzepatide in T2D obesity weight and glycemic efficacy (Garvey 2023, PMID 37385275)
Tirzepatide vs semaglutide head-to-head (2025) both, obesity tirzepatide superior for weight (Aronne 2025, PMID 40353578)
  • Network meta-analysis (764 trials, 421,346 patients): both classes lower all-cause and CV mortality and kidney failure; SGLT2i better for HF hospitalization, GLP-1RA better for stroke (Palmer 2021, PMID 33441402). A living BMJ clinical practice guideline now integrates cardiovascular, kidney, and weight effects across drug classes (Agarwal 2025, PMID 40813129).
  • GLP-1RA renal signals were visible as early as LEADER's secondary analyses (Mann 2017, PMID 28854085).

Guidelines - ADA/EASD 2022 consensus: holistic, person-centered management; SGLT2i/GLP-1RA recommended for organ protection independent of HbA1c or metformin use in those with CV/kidney disease (Davies 2022, PMID 36148880). - ADA Standards of Care 2026: pharmacologic approaches (PMID 41358900), CVD and risk management (PMID 41358899), microvascular complications (PMID 41358886).

Remission evidence - DiRECT: total diet replacement (~850 kcal/day) then structured reintroduction in primary care → 46% remission at 1 year (OR 19.7 vs control) (Lean 2018, PMID 29221645); 36% at 2 years (Lean 2019, PMID 30852132); with continued low-intensity support, 13% of the extension cohort remained in remission at 5 years with mean 6.1 kg maintained loss (Lean 2024, PMID 38423026). - Metabolic surgery: STAMPEDE 5-year outcomes — HbA1c ≤6.0% in 29% (gastric bypass) and 23% (sleeve) vs 5% with medical therapy alone (Schauer 2017, PMID 28199805). - Prevention is proven: DPP lifestyle intervention cut incident diabetes by 58% (metformin 31%) in high-risk adults (Knowler 2002, PMID 11832527), with effects persisting over 15 years (DPPOS 2015, PMID 26377054). Intensive lifestyle intervention in established T2D (Look AHEAD) did not reduce CV events but shows mortality-relevant subgroup signals in long-term follow-up (Look AHEAD 2022, PMID 35312758).

Research frontier

  • Triple agonists and next-generation incretins pushing weight loss toward surgical territory; head-to-head obesity trials are now the battleground (Aronne 2025, PMID 40353578).
  • Whether incretin-era weight loss converts to durable remission at scale, and how remission should be maintained after drug withdrawal (Riddle 2021, PMID 34462270; Lean 2024, PMID 38423026).
  • Precision diabetes medicine: subclassifying T2D by pathophysiology to target therapy (Tobias 2023, PMID 37794253).
  • Ending diabetes stigma as a measurable care outcome — an international consensus now frames it as a system problem (Speight 2024, PMID 38128969).

How to use this condition map

Question Start with
How common and costly is T2D? Epidemiology and burden
Can it be prevented or reversed? Prevention; remission
Which drug protects heart/kidney? Incretins; SGLT2 inhibitors
What did classic glucose trials prove? Glycaemic management
When is surgery evidence-based? Metabolic surgery
Why is young-onset disease different? Youth-onset T2D
What requires urgent action? Red flags and safety
What is unresolved? Open questions

Evidence-reading cautions

  • “Diabetes” estimates may include all types and different age ranges.
  • HbA1c effects do not substitute for cardiovascular or kidney outcomes.
  • Remission denominators and medication rules must be stated.
  • Relative effects require baseline risk for clinical meaning.
  • Network comparisons are not head-to-head randomisation.
  • Registry completion does not guarantee published results.

What the broader evidence changes

Diabetes is a multi-axis disease, not an HbA1c diagnosis alone

DeFronzo's “ominous octet” formalised eight interacting defects—muscle, liver, β-cell, adipose tissue, gut incretin signalling, α-cell glucagon, kidney glucose reabsorption and brain appetite/metabolic signalling—rather than a single insulin-resistance pathway (DeFronzo 2009, PMID 19336687). This framework explains why lowering glucose through one mechanism can leave cardiovascular, kidney, weight and hypoglycaemia risks substantially unchanged.

Steno-2 provides the landmark test of multi-axis treatment. Among 160 adults with T2D and microalbuminuria, simultaneous targets for glucose, blood pressure, lipids, renin–angiotensin blockade, aspirin and behaviour reduced the cardiovascular composite by 53% over 7.8 years (HR 0.47, 95% CI 0.24–0.73) (Gaede 2003, PMID 12556541). At 13.3 years, all-cause death was 24/80 versus 40/80 (HR 0.54, 95% CI 0.32–0.89), cardiovascular death HR 0.43 (0.19–0.94), and cardiovascular events HR 0.41 (0.25–0.67) (Gaede 2008, PMID 18256393). At 21.2 years, the original intensive group had median survival 7.9 years longer, although the trial was small and enrolled a selected microalbuminuric population (HR for death 0.55, 95% CI 0.36–0.83) (Gæde 2016, PMID 27531506).

Scale, treatment gaps and evidence breadth

Question Deepened evidence Interpretation
How large is the measurable adult burden? 828 million adults ≥18 years (95% credible interval 757–908 million) in 2022 across 1,108 population-representative studies This all-diabetes estimate uses different ages and tests from IDF/GBD and must not be averaged with them (NCD-RisC 2024, PMID 39549716)
How broad is the drug evidence base? Living network meta-analysis: 869 trials, 493,168 participants, 13 classes and 26 outcomes Large networks increase precision but retain indirect-comparison and trial-selection limitations (Nong 2025, PMID 40813122)
Is organ protection confined to one class? SGLT2 inhibitors and GLP-1RAs lower mortality/MACE; SGLT2 inhibitors more clearly lower HF and CKD progression, while GLP-1RAs more clearly lower stroke Benefits and harms differ by class and baseline risk; “newer is better” is not a sufficient treatment rule (Drake 2024, PMID 38639549)
Does adding GLP-1RA to background SGLT2 therapy preserve benefit? Trial-level subgroup meta-analysis found GLP-1RA cardiovascular/kidney effects consistent with and without baseline SGLT2 use Supports biological complementarity, but is not a randomised combination-versus-single-agent outcome trial (Neuen 2024, PMID 39210781)
How common is real-world remission? 10,694/338,791 assessable insured US adults (3.2%) met the 2021 consensus definition; alternative definitions yielded 0.8%–2.3% Remission prevalence is definition- and data-availability-dependent (Sheils 2023, PMID 37583561)
Does remission trajectory matter? In 60,287 people, stable low HbA1c was associated with lower microvascular (aHR 0.59, 95% CI 0.55–0.64), macrovascular (0.66, 0.61–0.71) and CVD-event risk (0.67, 0.61–0.73) than stable high HbA1c Observational association supports outcome relevance but cannot prove remission itself caused the reduction (Dambha-Miller 2023, PMID 37643199)

The resulting portrait is deliberately plural: T2D can be prevented or remitted in some people, progresses rapidly in others, and requires concurrent glycaemic, cardiovascular, kidney, weight and treatment-burden decisions. No single trial population or biomarker represents that full space.

Open questions

  • How durable is remission — DiRECT fell from 46% (year 1) to 13% (year 5 extension); is relapse driven by weight regain alone or by irreversible β-cell attrition? (Lean 2018, PMID 29221645; Lean 2024, PMID 38423026)
  • Do GLP-1RA-induced remissions (drug-dependent normoglycemia) count as remission at all under the consensus definition, and what happens on withdrawal? (Riddle 2021, PMID 34462270)
  • Can health systems afford population-scale incretin therapy when 536.6M adults have diabetes and expenditures already run $966B/year — and who gets priority? (Sun 2022, PMID 34879977; Agarwal 2025, PMID 40813129)
  • Why is youth-onset T2D so much more aggressive than adult-onset, and do incretins/SGLT2i change its complication trajectory? (TODAY 2021, PMID 34320286)
  • The UKPDS legacy effect implies early intensive treatment pays off for decades — does the same apply to early SGLT2i/GLP-1RA exposure, or is their benefit purely on-treatment? (Adler 2024, PMID 38772405; Palmer 2021, PMID 33441402)

References

  1. Sun H, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022. PMID 34879977
  2. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050. Lancet. 2023. PMID 37356446
  3. Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015. PMID 26378978
  4. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016. PMID 27295427
  5. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016. PMID 27633186
  6. Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019. PMID 31185157
  7. Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019. PMID 30990260
  8. Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. PMID 38785209
  9. Mann JFE, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017. PMID 28854085
  10. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID 37952131
  11. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. PMID 34170647
  12. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID 35658024
  13. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023. PMID 37385275
  14. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. PMID 40353578
  15. Palmer SC, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2021. PMID 33441402
  16. Agarwal A, et al. Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline. BMJ. 2025. PMID 40813129
  17. Lean ME, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018. PMID 29221645
  18. Lean MEJ, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT trial. Lancet Diabetes Endocrinol. 2019. PMID 30852132
  19. Lean ME, et al. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT). Lancet Diabetes Endocrinol. 2024. PMID 38423026
  20. Riddle MC, et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care. 2021. PMID 34462270
  21. Schauer PR, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. N Engl J Med. 2017. PMID 28199805
  22. Taylor R. Calorie restriction and reversal of type 2 diabetes. Expert Rev Endocrinol Metab. 2016. PMID 30058916
  23. Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and EASD. Diabetes Care. 2022. PMID 36148880
  24. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998. PMID 9742976
  25. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998. PMID 9742977
  26. Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008. PMID 18784090
  27. Adler AI, et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024. PMID 38772405
  28. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002. PMID 11832527
  29. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the DPP Outcomes Study. Lancet Diabetes Endocrinol. 2015. PMID 26377054
  30. TODAY Study Group. Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med. 2021. PMID 34320286
  31. Nathan DM, et al. Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes. N Engl J Med. 2022;387:1063-1074. PMID 36129996
  32. GRADE Study Research Group. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med. 2022. PMID 36129997
  33. Look AHEAD Research Group. Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults With Type 2 Diabetes and Overweight/Obesity: Results From the Look AHEAD Study. Diabetes Care. 2022. PMID 35312758
  34. Rawshani A, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017. PMID 28402770
  35. Tobias DK, et al. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med. 2023. PMID 37794253
  36. Speight J, et al. Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations. Lancet Diabetes Endocrinol. 2024. PMID 38128969
  37. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026. PMID 41358893
  38. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026. PMID 41358900
  39. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026. PMID 41358899
  40. American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026. Diabetes Care. 2026. PMID 41358886
  41. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795. PMID 19336687
  42. Gaede P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393. PMID 12556541
  43. Gaede P, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591. PMID 18256393
  44. Gæde P, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59:2298-2307. PMID 27531506
  45. Neuen BL, et al. Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes. Circulation. 2024;150:1781-1790. PMID 39210781
  46. Nong K, et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. BMJ. 2025;390:e083039. PMID 40813122
  47. Drake T, et al. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes. Ann Intern Med. 2024;177:618-632. PMID 38639549
  48. Dambha-Miller H, et al. Type 2 diabetes remission trajectories and variation in risk of diabetes complications. PLoS One. 2023;18:e0290791. PMID 37643199
  49. Sheils NE, et al. Real-World Prevalence of Type 2 Diabetes Remission in a U.S. Insured Population. Diabetes Spectr. 2023;36:211-218. PMID 37583561
  50. NCD Risk Factor Collaboration. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022. Lancet. 2024;404:2077-2093. PMID 39549716